Abstract：
Liver fibrosis is a chronic liver lesion caused by excessive deposition of the extracellular matrix after liver damage, resulting in fibrous scarring of liver tissue. The progression of liver fibrosis is partially influenced by the gut microbiota. Chitosan can play a therapeutic role in liver fibrosis by regulating the gut microbiota based on the \'gut-liver axis\' theory. Salvianolic acid B can inhibit the development of liver fibrosis by inhibiting the activation of hepatic stellate cells and reducing the production of extracellular matrix. In this study, the therapeutic effect of chitosan in combination with salvianolic acid B on liver fibrosis was investigated in a mouse liver fibrosis model. The results showed that the combination of chitosan and salvianolic acid B was better than the drug alone, improving AST/ALT levels and reducing the expression of α-SAM, COL I, IL-6 and other related genes. It improved the structure of gut microbiota and increased the abundance of beneficial bacteria such as Lactobacillus. The above results could provide new ideas for the clinical treatment of liver fibrosis.
摘要：
肝纤维化是肝损伤后细胞外基质过度沉积引起的慢性肝损害,导致肝组织纤维性瘢痕。肝纤维化的进展部分受到肠道微生物群的影响。基于“肠-肝轴”理论，壳聚糖可以通过调节肠道菌群在肝纤维化中发挥治疗作用。丹酚酸B可以通过抑制肝星状细胞的活化和减少细胞外基质的产生来抑制肝纤维化的发展。在这项研究中,在小鼠肝纤维化模型中研究壳聚糖联合丹酚酸B对肝纤维化的治疗作用。结果表明,壳聚糖与丹酚酸B联用效果优于单用药物,提高AST/ALT水平，降低α-SAM的表达，COLI,IL-6等相关基因。它改善了肠道微生物群的结构，增加了有益细菌如乳酸菌的丰度。以上结果可为肝纤维化的临床治疗提供新思路。
